x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Dr RR Baliga"s "Got Knowledge Doc" Podkast

Dr RR Baliga, MD, MBA

"Got Knowledge Doc" Podkast with Dr. RR Baliga The "Got Knowledge Doc" Podkast, hosted by Dr. Ragavendra R. Baliga, is a knowledge-driven platform designed for physicians and healthcare providers seeking to stay at the forefront of medical science and innovation. With a distinguished career in cardiovascular medicine and academic leadership, Dr. Baliga engages with leading experts to explore cutting-edge research, emerging technologies, and transformative insights in medicine and beyond. Each

science natural sciences

All Episodes

03:17

🎨 Art, Health & Hope: Preventing noncommunicable...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/21

🎭 Just explored a landmark Nature Medicine review on how the arts can prevent noncommunicable diseases (NCDs) across 27 countries! 🎨 From dance and drama to gardening and storytelling, arts-based interventions improved physical activity, diet, and mental well-being—especially in underserved communities. 📊 A must-read for anyone interested in health equity, cultural relevance, and community-led innovation in public health. 👇 Dive into the power of creativity for prevention! #NCDs #ArtsInHealth

en

03:25

🌍 Obesity, Orals, Outcomes: Rewriting the GLP-1 Script

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/21

💊 Orforglipron: A new era in obesity treatment? In the ATTAIN-1 trial, this oral, nonpeptide GLP-1 receptor agonist delivered up to 11.2% weight loss over 72 weeks—with significant drops in waist circumference, triglycerides, and blood pressure 📉🌡️ 🔥 Nearly 1 in 5 patients lost ≥20% body weight 💡 A promising alternative to injectable therapies Accessible. Effective. Oral. 👉 A game-changer for global obesity care? #Obesity #GLP1 #Orforglipron #WeightLoss #CardiometabolicHealth #NEJM

en

07:08

HCM in Two Acts 🎭: Aficamten, Mavacamten & Dueling...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/20

🚨 New Podcast Drop! 🎙️ “Myosin, Metrics & Momentum 🧬📈🫀” dives into 3 landmark NEJM articles on Aficamten vs Mavacamten in hypertrophic cardiomyopathy. We decode: 🔹 MAPLE-HCM (obstructive HCM) 🔹 ODYSSEY-HCM (nonobstructive HCM) 🔹 Expert editorial insights on PROs, EF, & trial design 🎯 Learn what matters: peak VO₂ vs PROs, safety signals, and the road ahead in precision cardiomyopathy care. 🎧 Tune in and share! #HCM #CardioTwitter #NEJM #HeartFailure #MyosinInhibitors #Podcast

en

04:12

🧬 Science, Slimming, and Semaglutide Redefining...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/20

💊 New Hope in a Pill for Obesity? The 71-week OASIS 4 trial shows that oral semaglutide 25 mg led to a 13.6% weight loss, improved physical function, and reversed prediabetes in 71% of cases—all without injections. 📉 Effective. 🧬 Metabolically beneficial. 📦 Orally delivered. #ObesityCare #GLP1 #Semaglutide #NEJM #DigitalHealth #Cardiometabolic

en

03:23

🌞 Sun, Skin & Science: The Bright Side of Exposure

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/20

☀️ Walking on Sunshine? Rethinking Our Relationship with the Sun! 🧴🧬 New research—spotlighted in The Economist (Sep 20, 2025)—challenges old assumptions: Could moderate sun exposure reduce cardiovascular mortality? ❤️📉 From nitric oxide to vitamin D, this FAQ explores the science, nuance, and shifting global guidelines. Let’s talk melanin, mortality, and medicine! 🌍💡 #Sunlight #CardiovascularHealth #TheEconomist #PublicHealth #MedicalEducation

en

04:46

🫀 Cardiogenic Shock Survival: Impella’s Decade-Long...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/18

🚨 Cardiogenic Shock—A Decade Later The DanGer Shock Trial shows that patients with STEMI and shock treated with the Impella CP microaxial flow pump lived 600 more days over 10 years vs standard care alone. 📉 Mortality: 52.5% vs 68.8% (HR 0.70) 🛠️ Despite higher adverse events, the survival benefit endured a full decade. 📊 This changes how we think about long-term outcomes in mechanical support. 🔗 Time to revisit your shock protocols? #DanGerShock #Impella #CardiogenicShock #STEMI

en

07:06

💓 Genes, Gradients, and Game-Changers: FAQs on...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/17

🧠 Hypertrophic Cardiomyopathy — A Masterclass from Eugene Braunwald 🧬 📌 Just published in NEJM (Aug 2025): a sweeping, state-of-the-art review on HCM — from Teare’s first autopsy to myosin inhibitors, AI diagnostics, and gene therapy. 💥 Clinical insights, historical depth, trial data (EXPLORER-HCM, SEQUOIA-HCM, VALOR-HCM), and future-facing advances—all distilled into one must-read. 📉 SCD prevention, 🫀 LVOT obstruction, 🧪 MYBPC3/MYH7 mutations, 🧬 proteomics, and more. 🔗 Essential

en

04:42

🔬 Silence APOC3, Slash Triglycerides, A New Era in...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/16

🚨 New NEJM Study on Olezarsen 🚨 In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, monthly subcutaneous olezarsen reduced triglycerides by over 60% at 6 months! 📉💥 ✅ Significant drops in APOC3, VLDL, remnant & non-HDL cholesterol ✅ No rise in LDL-C ✅ Well-tolerated with mild injection-site reactions 🔬 APOC3 inhibition emerges as a game-changer in lipidology. 📖 ESSENCE–TIMI 73b Trial | Funded by Ionis Pharmaceuticals #Cardiology #LipidLowering

en

03:24

Dr RR Baliga's Philosophical Discourses: Dogen...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/16

🌸 Dōgen Zenji (1200–1253), founder of the Sōtō Zen school in Japan, taught that true practice lies in zazen—“just sitting” 🧘‍♂️—where enlightenment and practice are inseparable. His Shōbōgenzō continues to inspire mindfulness & presence today. ⏳✨ #Zen #Mindfulness

en

05:11

NSTEMI: 📉 Less Ischemia, Less Reintervention

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/05

🚨 New Evidence in NSTEMI Care! 🫀 The SLIM Trial shows that FFR-guided complete revascularization during the index procedure in patients with NSTEMI and multivessel disease significantly reduces death, MI, stroke, and repeat PCI compared to culprit-only PCI. 🎯 Key win? Fewer revascularizations, better outcomes — physiology beats anatomy again. 📚 Published in JAMA, presented at #ESC2025 🔗 Read more: https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2025.16189 #Cardiology #NSTEMI

en

06:04

Real-World Rx 💊, Real Results 📉: GLP-1 Agents Slash...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/05

💥 Practice-Changing Evidence in HFpEF! 💥 In a real-world cohort of 97,000+ patients with obesity & type 2 diabetes, semaglutide and tirzepatide reduced risk of heart failure hospitalization or death by over 40% 📉 ⚖️ No meaningful difference between the two agents. 🧠 Findings reinforce STEP-HFpEF & SUMMIT trials and highlight GLP-1 therapies’ expanding role in cardiometabolic HFpEF 🫀 #Cardiology #HFpEF #GLP1 #Semaglutide #Tirzepatide #T2DM #RealWorldEvidence #JAMA #HeartFailure

en

03:20

The AMALFI AF Screening Trial-📈 Atrial Fibrillation...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/04

📢 Just read the #AMALFI trial in JAMA 📰 — a landmark remote RCT of AF screening using 14-day ECG patches mailed to older adults at stroke risk 📦🫀. At 2.5 years, the patch group had a modestly higher AF detection rate (6.8% vs 5.4%, p=0.03) and increased anticoagulation use 💊🧠. Stroke rates were similar ⚖️. 🎯 Key takeaway: Remote, mail-based AF screening is feasible and nudges diagnosis rates — but will it move the needle on outcomes? #AFib #StrokePrevention #RemoteMonitoring #ECG

en

05:14

🛑 AFib Gone, OAC Gone? ALONE-AF Challenges Lifelong...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/04

🚨 New Trial Alert 🚨 Can we safely stop anticoagulation after AF ablation? The ALONE-AF Trial 🫀 suggests yes—in selected patients with no AF recurrence, stopping DOACs reduced major bleeding 🌟 without increasing stroke risk 🧠. 📉 0.3% vs 2.2% for the composite outcome (P = .02) 📍 Carefully monitored, low-risk patients may benefit most. 📝 Editorial: Recommends shared decision-making 🤝 & individualized rhythm monitoring. 📚 A potential shift in post-ablation care. 🔗 #AFib

en

05:16

🦠💔Bugged After the Heartbreak? Does H. pylori...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/03

🚨 New Findings from the HELP-MI Trial! 🇸🇪🧪 Can routine Helicobacter pylori screening during acute myocardial infarction (MI) hospitalization prevent upper gastrointestinal bleeding (UGIB)? 💉 Over 18,000 patients across 35 Swedish hospitals 📉 Result: No significant reduction in UGIB overall (RR 0.90; P=0.18) 🔍 BUT: Clear benefit in patients with anemia (RR 0.44–0.64) and chronic kidney disease (RR 0.75) 🧠 Key Takeaway: Routine screening isn’t broadly warranted—but targeted testing in

en

03:33

🧬 Risk, Recurrence, Relief: Apixaban’s Edge in VTE 🌡️...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/02

🩺 New Insights on Apixaban for VTE! 📢 The HI-PRO trial challenges the old 3-month rule for provoked VTE. 📉 Extended low-dose apixaban (2.5 mg BID) reduced recurrent VTE from 10.0% ➡️ 1.3% with minimal major bleeding. 🎯 Editorial in NEJM urges a shift from binary labels (“provoked vs unprovoked”) to a patient-centered, risk-adapted approach. 🧠 Art meets evidence in the decision to extend anticoagulation. 💬 Let’s rethink how we label, risk-stratify, and treat. 📚 #VTE #Apixaban

en

04:04

Dr RR Baliga's Philosophical Discourses: Zhu Xi...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/02

🌏 Zhu Xi (1130–1200), a master of Neo-Confucianism, reshaped Chinese philosophy with his focus on rationality, self-cultivation & education. His commentaries on the Four Books guided civil service exams for centuries across East Asia. 📚✨ #Leadership #Philosophy #History #Confucianism

en

05:23

Gait Speed. Grip Strength. Greater Life. 🦵🤝🌟 A...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/01

Just read the latest from NEJM? The PIpELINe Trial 🇮🇹 changes how we approach cardiac rehab in older adults post-MI! 🧓❤️ 🎯 A 12-month, multidomain intervention — risk factor control, nutrition 🥗, and Otago-based exercise 👟 — cut CV death/hospitalization from 20.6% → 12.6% (P=0.01)! 📉 Hospitalizations for heart failure dropped 7.1% → 1.5%. No serious adverse events. And yes — better gait speed, handgrip strength, and quality of life too. This is how we shift from survival ➡️ functional

en

04:03

💊 Block. Beat. Benefit. The Hidden Strength of...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/09/01

🚨 New Meta-Analysis Alert! 💊🫀 Can β-blockers benefit patients post-MI with mildly reduced ejection fraction (LVEF 40–49%)? 📊 An individual patient data meta-analysis (REBOOT, BETAMI, DANBLOCK, CAPITAL-RCT) shows a 25% reduction in the composite outcome of death, MI, or HF with β-blockers vs. control (HR 0.75; p=0.031) — even in the absence of clinical heart failure. 🌍 Consistent across trials and countries. Most benefit seen in patients <75 years. 📚 This could shift guidelines for a large

en

04:59

🧠 REBOOTing Beta-Blockers – No Gains ⚖️ After Modern...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/31

🚫💊 Should We Rethink Beta-Blockers Post-MI? In the landmark REBOOT trial (NEJM, 2025), beta-blockers failed to reduce mortality, reinfarction, or heart failure hospitalizations in post-MI patients with preserved ejection fraction (>40%). 💡 A modern, pragmatic trial across 109 centers (Spain + Italy 🇪🇸🇮🇹) with 8438 patients — shaking the foundation of our long-held post-MI practices. 👩‍⚕️ Signals of potential harm in women and STEMI subgroups raise questions, not answers. 📉 Should

en

04:49

Beta Blockers in MI: Old Drug, New Lens, Possible Win...

Dr RR Baliga"s "Got Knowledge Doc" Podkast ·

2025/08/31

🚨 New NEJM Study Alert! 🩺💔 Do beta-blockers still help after a heart attack if there’s no heart failure? 🤔 In the BETAMI–DANBLOCK trial (🇩🇰+🇳🇴, n=5574), beta-blocker therapy in post-MI patients with preserved or mildly reduced LVEF (≥40%) modestly reduced the composite outcome of death or major cardiovascular events 🧠📉 📌 Primary endpoint: 14.2% (BB) vs. 16.3% (no BB) → HR 0.85, p=0.03 💡 Especially lowered risk of recurrent MI (HR 0.73) 🧠 Even in the era of PCI, DAPT & statins,

en

842 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter